ProfileGDS5678 / 1450400_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 80% 79% 79% 79% 82% 81% 80% 79% 79% 79% 79% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4345879
GSM967853U87-EV human glioblastoma xenograft - Control 25.7518580
GSM967854U87-EV human glioblastoma xenograft - Control 35.5007879
GSM967855U87-EV human glioblastoma xenograft - Control 45.6011479
GSM967856U87-EV human glioblastoma xenograft - Control 55.497379
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7072482
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6833281
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5705180
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4858979
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5178679
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4914779
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5446679
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4634379
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5358179